Henning Mann, PhD, HM.BioConsulting “Growth in this field depends on reaching the toxicologists, clinical development leads, and investment committees who have never encountered the term “context of use.” That conversation has to leave the MPS and NAM bubble.” Download PDF" 🚨 Regulator-Backed Policy Changes and Momentum In April 2025, the FDA published its Roadmap to Reducing Animal Testing in Preclinical Safety Studies, a stepwise plan to phase down reliance on animal mod